Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...

We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, ...

Image source: Getty Images. Comparing Eli Lilly and Viking Therapeutics. Every market leader started somewhere, and Eli Lilly's history of innovation spans 149 years since its founding in 1876.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Within the pharmaceuticals industry in particular, shares of Eli Lilly (LLY 1.33%), Novo Nordisk (NVO-1.50%), and Viking Therapeutics (VKTX-0.23%) are all looking to close out the week strong.

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all downside hedges. Despite trading near 52-week lows due to biotech industry ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a ...

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday. Rich Smith, The Motley Fool. May 2, 2025 at 11:55 AM. Copied; ...

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday May 02, 2025 — 11:55 am EDT Written by Rich Smith for The Motley Fool -> ...